Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma

• Published in: Advanced science Vol. 11; no. 30; pp. e2401789 - n/a
• Main Authors: Zheng, Ying, Ye, Shengtao, Huang, Shiyu, Cheng, Yang, Zhang, Yanqiu, Leng, Yingrong, He, Mengmeng, Wu, Enyi, Chen, Junxin, Kong, Lingyi, Zhang, Hao
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.08.2024; John Wiley and Sons Inc; Wiley
• Subjects: acetylation; Animals; Antibiotics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Benzofurans; Biosynthesis; Breast cancer; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - metabolism; Cell cycle; Cell death; Cell growth; Cell Line, Tumor; Disease Models, Animal; Diterpenes - pharmacology; Drug resistance; Drug Resistance, Neoplasm - drug effects; FDA approval; Federal regulation; Gene expression; HCC; Homeostasis; Homeostasis - drug effects; Humans; ILF3; Kinases; lefamulin; Libraries; Limonins - pharmacology; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - metabolism; Metabolism; Mice; Mitochondria - drug effects; Mitochondria - metabolism; MRPL12; Naphthoquinones; Nuclear Factor 90 Proteins - genetics; Nuclear Factor 90 Proteins - metabolism; Pneumonia; Polycyclic Compounds - pharmacology; Polycyclic Compounds - therapeutic use; Proteins; Respiration; RNA polymerase; Sorafenib - pharmacology; targeted therapy resistance; Toxicity; Tumors; acetylation; HCC; ILF3; lefamulin; MRPL12; targeted therapy resistance

Acquired resistance represents a critical clinical challenge to molecular targeted therapies such as tyrosine kinase inhibitors (TKIs) treatment in hepatocellular carcinoma (HCC). Therefore, it is urgent to explore new mechanisms and therapeutics that can overcome or delay resistance. Here, a US Foo...